A study reveals response markers for immunotherapy in advanced melanoma
The journal Nature has published a study led by the Memorial Sloan Kettering (MSK) of New York and the University of Pennsylvania which shows that immunotherapy for melanoma (anti-PD1) is more effective when the tumour burden is lower. This study, which counts with the participation of the researcher Cristina Carrera, from Hospital Clinic -IDIBAPS - UB, has also identified blood markers that enable predicting each patientʼs response to the treatment in the first four or six weeks. In particular, researchers stated that knowing the amount of reinvigorated T-cells related to the tumour burden when starting the therapy allows them to predict its potential clinical benefit, and identify those patients with a null or insufficient response.
Further information [Catalan]
The journal Nature has published a study led by the Memorial Sloan Kettering (MSK) of New York and the University of Pennsylvania which shows that immunotherapy for melanoma (anti-PD1) is more effective when the tumour burden is lower. This study, which counts with the participation of the researcher Cristina Carrera, from Hospital Clinic -IDIBAPS - UB, has also identified blood markers that enable predicting each patientʼs response to the treatment in the first four or six weeks. In particular, researchers stated that knowing the amount of reinvigorated T-cells related to the tumour burden when starting the therapy allows them to predict its potential clinical benefit, and identify those patients with a null or insufficient response.
Further information [Catalan]
Article reference:
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. «T-cell invigoration to tumour burden ratio associated with anti-PD-1 response». Nature, May 4, 2017. Doi: 10.1038/nature2207